Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis

Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be another pivotal setback for its pipeline.